Recursion Pharmaceuticals, Inc.
RXRX
$4.50
$0.184.05%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.61% | 15.11% | -13.18% | -86.67% | 1.74% |
| Total Depreciation and Amortization | -11.77% | 23.37% | 49.26% | 79.92% | -19.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.47% | -36.06% | 28.27% | 49.84% | 116.87% |
| Change in Net Operating Assets | -174.80% | 700.70% | -196.76% | 2,390.91% | 96.40% |
| Cash from Operations | -53.58% | 42.09% | -14.32% | -94.90% | 27.97% |
| Capital Expenditure | 92.29% | -71.94% | -41.14% | 71.55% | -285.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 100.00% | -- | -- | -- |
| Other Investing Activities | 13.24% | -165.80% | -185.71% | -- | 100.00% |
| Cash from Investing | 56.11% | 20.11% | -102.64% | 6,138.05% | -9.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.06% | -1.81% | 2.57% | 8.13% | -8,696.15% |
| Issuance of Common Stock | 146.70% | 141.33% | 234.18% | -32.05% | -92.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | 157.36% | 140.97% | 280.93% | -35.37% | -93.74% |
| Foreign Exchange rate Adjustments | -79.81% | 91.50% | 239.20% | -961.54% | 441.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 439.94% | 126.30% | -156.14% | 456.32% | -126.57% |